Salk Institute scientists discovered a relationship between killer T-cell exhaustion and the body’s sympathetic stress response, or “fight-or-flight,” in varying cancer types in mouse and human tissue samples.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
